Ionis won an early approval with a broader age label than its primary endpoint population. Advicenne withdrew its application before its decision date. AstraZeneca secured a mutation-triggered breast-cancer approval—with a confirmatory obligation still attached.
The next live clock is Telix on Friday. This issue tracks eight remaining September target dates, with five concentrated between September 26 and September 30.
This week's distinction: a diagnostic-evidence repair is not the same setup as a manufacturing repair—even when both arrive as resubmissions.
| Date | Sponsor / ticker | Event | Setup class | Main risk | PoA |
|---|---|---|---|---|---|
| Fri Sep 11 | Telix / TLX | TLX101-Px (Pixclara) / glioma PET imaging | Resubmitted NDA; Fast Track / Orphan Drug | Diagnostic evidence / resubmission execution | 75% |
| Sat Sep 19* | RARE | UX111 / Sanfilippo syndrome type A | Resubmitted BLA; accelerated-approval request | CMC / facility remediation | 79% |
| Mon Sep 21 | MRK | WINREVAIR / HYPERION-based PAH label update | sBLA | Label scope / execution | 96% |
| Sat Sep 26* | Mirum / Incyte · MIRM / INCY | zilurgisertib / FOP, ages 12+ | Priority Review NDA | Pivotal evidence / benefit-risk / label | 78% |
| Mon Sep 28 | Egetis (Stockholm-listed) | Emcitate / MCT8 deficiency | Priority Review NDA | Rare-disease evidence / label | 83% |
| Mon Sep 28 | BFRI | Ameluz + RhodoLED / superficial basal cell carcinoma | sNDA; drug-device indication expansion | Treatment protocol / label | 85% |
| Wed Sep 30 | BMY | CAMZYOS / symptomatic obstructive HCM, ages 12–<18 | Priority Review sNDA | Pediatric label / safety monitoring | 91% |
| Wed Sep 30 | SRRK | apitegromab / spinal muscular atrophy | BLA resubmission | Fill-finish facility / CMC execution | 74% |
Saturday targets: distinguish FDA action from the timing of the public announcement. PoAs are unchanged from last week's issue for these eight applications.
Date sources: Telix, Ultragenyx, Merck, Mirum, Egetis, Biofrontera, Bristol Myers Squibb, Scholar Rock.
IONS / ZANVASTRO — APPROVED SEP 3
FDA approved zilganersen for pediatric and adult patients with Alexander disease, ahead of the September 22 target. Last week's age-boundary question now has an answer: the indication is not limited to the five-and-older population used for the primary walking-speed endpoint.
FDA describes supporting motor-function evidence in younger children and pharmacokinetic modeling plus limited safety data in infants. That is a population-specific evidentiary bridge—not a claim that the same endpoint was demonstrated at every age. Aseptic meningitis remains a labeled safety concern. FDA approval.
ADVICENNE / ADV7103 — NDA WITHDRAWN AUG 31
Advicenne voluntarily withdrew its U.S. application for primary distal renal tubular acidosis. The company said additional CMC work could not be completed within the review cycle. September 3 is therefore neither a pending decision nor a presumed CRL. The withdrawal release did not provide a replacement U.S. action date. Company announcement.
AZN / ETCAMAH — ACCELERATED APPROVAL SEP 4
Camizestrant plus a CDK4/6 inhibitor was approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer when an ESR1 mutation is detected during aromatase-inhibitor/CDK4/6 treatment using an FDA-authorized test.
The approval followed an April 30 ODAC vote of 3 in favor and 6 against a favorable benefit-risk assessment. In May, FDA extended the review to consider additional requested analyses, including ctDNA clearance linked to longer-term outcomes. The advisory vote was not the final regulatory decision. Advisory vote, review extension.
The important shift is treatment before clinical progression: SERENA-6 enrolled patients without disease progression. Median PFS was 16.0 versus 9.2 months; overall-survival data were immature. Continued approval may depend on confirmatory evidence. The label also carries a boxed warning for arrhythmia risk when used with QTc-prolonging drugs. An early molecular switch has an approval—but not an established survival benefit. FDA decision.
PHARMAESSENTIA / BESREMi — AUGUST CLOCK RESOLVED
The ET indication covers adults, without a hydroxyurea-failure restriction in the indication itself. Yet SURPASS ET enrolled 174 adults with an inadequate response or intolerance to hydroxyurea. The approved population is broader than that pivotal trial population—a distinction between what was directly studied and whom the label permits treating. FDA's approval record dates the action to August 28; its public announcement followed August 31. FDA approval record, FDA announcement.
PDUFA: Friday, September 11
Setup: Resubmitted NDA
Risk: Diagnostic evidence / execution
PoA: 75%
The clean read: This is an evidence-repair application. Following its earlier CRL, Telix said FDA feedback called for an additional confirmatory efficacy analysis using existing data. Agreement on a resubmission pathway did not itself settle the adequacy of that evidence. Resubmission pathway.
What matters:
Current application and target.
PDUFA: Saturday, September 19
Setup: Resubmitted BLA seeking accelerated approval
Risk: CMC / facility remediation
PoA: 79%
The clean read: The prior CRL centered on CMC information and manufacturing-inspection observations. Ultragenyx reported that FDA viewed the neurodevelopmental data as robust and the biomarker evidence as supportive. The principal repair thesis is manufacturing—not an assertion that clinical efficacy failed. Those favorable comments are company-reported, not a completed approval decision. Prior CRL disclosure.
What matters:
The company context changed this week: On September 2, Ultragenyx reported that apazunersen (GTX-102) missed both the primary cognitive endpoint and the key secondary multidomain endpoint in the Phase 3 Aspire trial in Angelman syndrome. The company is evaluating the program and planning significant expense reductions. That is material to the investment case, but it is a different molecule, modality and disease from UX111. We are holding UX111's application-specific PoA at 79%; that is not an unchanged assessment of the entire company. Aspire results.
Scholar Rock's September 2 Fast Track and Orphan Drug announcement concerns apitegromab in facioscapulohumeral muscular dystrophy, a separate development program. It does not resolve the SMA BLA's fill-finish review. FSHD announcement.
For September 30, the relevant sequence remains: the alternate facility was already in the resubmission. On August 7, customers were notified that FDA had classified Catalent Indiana's April general site inspection as Official Action Indicated (OAI). Scholar Rock subsequently removed Catalent from the U.S. application while FDA review continued with the alternate facility. It also withdrew the European application through a CHMP written procedure that concluded August 20, with plans to resubmit using the alternate facility. Those are the manufacturing facts that matter to the approval setup. U.S. review update, global regulatory update.
The distinction works in both directions: Scholar Rock's FSHD designation does not clear its SMA manufacturing review, and Ultragenyx's Angelman setback does not establish that UX111 failed clinically.
Company-level news can change the investment case without answering the application-level question.
Editorial risk map—not a forecast of undisclosed FDA findings.
| Name | First question after an adverse action |
|---|---|
| Telix | Did the supplemental diagnostic evidence resolve the earlier review concerns? |
| RARE / UX111 | Were CMC and facility corrective actions sufficient? |
| MRK / WINREVAIR | Was the requested HYPERION-based label change supported? |
| Mirum / Incyte | Did the FOP benefit-risk package support the proposed ages-12+ indication? |
| Egetis | What limitation did FDA identify in the evidence or proposed U.S. label? |
| BFRI | Did the sBCC evidence and drug-device treatment protocol support the expansion? |
| BMY / CAMZYOS | Did adolescent benefit-risk and monitoring support the proposed label? |
| SRRK | Was the remaining fill-finish package approvable within this cycle? |
First decision: Telix on Friday. The issue is the repaired diagnostic-evidence package.
Next resubmission: UX111 on September 19. Keep its manufacturing remediation distinct from the separate Aspire clinical setback.
Late-month concentration: Five targets in five calendar days—Mirum/Incyte, Egetis, Biofrontera, Bristol Myers Squibb and Scholar Rock.
What last week answered: Ionis received a broad age indication. Advicenne's current U.S. review ended in withdrawal. Camizestrant's approval moved the treatment decision earlier while leaving confirmatory evidence outstanding.
The useful question is not just whether FDA says yes. It is which patients, which claim, and which remaining obligation that yes covers.
Follow the FDA decision board. Forward this issue to someone tracking September's dates without tracking the questions behind them.
Informational only. Not investment advice. Biotech investing carries the risk of total loss.